This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Accepted for publication 21 June 2016 U RINARY INCONTINENCE (UI) is the loss of bladder control (involuntary loss of urine). It is a common health problem, especially among women. Rough population prevalence estimates for females range from 5% to 69% globally. Cultural differences, willingness to report UI, and methodological differences in research are factors impacting the variation between countries. Most studies report prevalence of any UI of 25-45%, with 10% of all adult women reporting weekly leakages. The prevalence distribution between UI subtypes is more consistent, with stress incontinence range of 10-39%, mixed incontinence (both stress and urgency-related) at a range of 7.5-25%, urgency incontinence with 1-7% prevalence, and all other causes of incontinence at 0.5-1% (1) . Urinary incontinence prevalence increases with age, implying UI impact will increase over the next several decades as the growing population ages. Known UI risk factors include increased body mass index, and diabetes; however, menopausal status does not appear to be an independent risk factor (1) . The effects of UI on skin barrier function are well known and can cause localized incontinenceassociated dermatitis (2) (3) (4) (5) .
Some women choose to manage their UI with protective garments as a lifestyle intervention. A new line of disposable options including pantiliners, pads, and protective underwear has been developed to better meet these needs. These new products contain a proprietary mixture of functional fragrance components that quickly neutralize amines as an odor neutralizing technology (ONT) within the absorbent core. The ONT components are covered by a non-woven top sheet intended for skin contact, and a back sheet that protects undergarments from wetness. The protective underwear product provides a fitted elastic waistband which holds the core in place to provide the extra reassurance of a fitted pant for heavier urine losses.
Assessment of dermatological effects of absorbent products intended for prolonged skin contact, such as menstrual products, baby diapers, and incontinence products is important to confirm good skin compatibility, and is aimed at ensuring these products are safe for intended and foreseeable use. The toxicology/risk assessment confirms all product materials have a sufficient margin of safety and are safe for their use in the product (3) . Clinical studies on finished product are typically conducted to confirm effects of product use on skin health. Thus, the present study evaluates the impact of experimental or currently marketed reference adult incontinence protective underwear on skin health in current incontinent protective underwear users during typical conditions of use over a period of 14 consecutive days. Skin complications (infections and other disorders) and slower wound healing are common in people with diabetes (6). Thus, the subject population includes diabetics (target 20%) to gain additional learning for known incontinence comorbidity with increased potential for skin health issues. In addition, since vulvovaginal symptoms in this population may include irritation, burning, itching, etc. (7), postmenopausal subjects are included to understand potential skin health issues in women with estrogen loss.
Skin health is assessed primarily by visual skin grading using a standard skin erythemagrading scale (Table 1) routinely used in skin patch and product in-use tests (8) (9) (10) (11) . Additional exploratory measures include visual skin grading using a skin-marking visual scoring scale (Table 2) used with babies and incontinent adults (unpublished data), a non-invasive objective measure of skin barrier health, transepidermal water loss (TEWL) (12) , and reported adverse events (AEs). We hypothesized measures of skin health would not be statistically different between the experimental and marketed reference products.
Methods
The study protocol and written subject information were approved by an independent Institutional Review Board. Women from St. Petersburg, Florida and San Antonio, Texas were informed about the products, nature of the clinical investigation (including potential AEs), and provided subject written informed consent prior to study procedures. Inclusion criteria included: ambulatory, non-pregnant If a subject exhibited a grade of ≥2.0 on assessment of any test site, test materials were not re-dispensed for the remainder of the trial and the site was graded to assess the erythema regression response. *The degree of reaction expressed by such descriptive terms as 'moderate' and 'severe' is, in itself, subjective. Such terminology can be accurately understood only through experience. Any reaction of greater severity than Grade 4 should be described in detail. Unusual reactions not described by the scale should also be described. For this skin erythema grading, the grader will first identify the area of greatest erythema intensity and if the area of greatest intensity is <25% of the whole area, reduce the score by 0.5 but if the area of greatest intensity is 25% or more of area, make no change to score. female ≥18 years of age, general good health (if diabetic, most recent HbA1c score <8%), >5 urine leakage events/week, using ≥5 protective underwear ≥5 days/week, and regular menstrual cycles (as applicable). Enrollment targeted ≤15% Fitzpatrick skin Type V and VI (13), 20% Type II diabetics. Exclusion criteria included: currently using antibiotics, chemotherapeutics, antihistamines, anti-inflammatories, corticosteroids, having any skin abnormalities that could interfere with interpretation of test results, loss of bowel control >1 per month, kidney disease, current hematuria, and evidence of urinary tract or genital infection. Subjects agreed to refrain from activities that would impact testing results, such as: (1) shaving, using depilatories, or applying skin care preparations in pubic or buttocks area, (2) using tobacco, alcohol, caffeine, or having sexual intercourse 2 h before study visits, and (3) vigorous (sweat producing) exercise, swimming and sun exposure.
Eligible subjects were recruited from the general public between October 2013 and February 2014, and randomized into two groups of maximum absorbency experimental or marketed protective underwear. Groups were stratified based on self-reported number of protective underwear used per day, the presence of diabetes, and waist measure. Products were worn non-menstrually for urine leakage protection (≤24 h/day) for 14 days and subjects recorded underwear wear time, used underwear weight (using the provided balance), and leakage information on a daily diary. Visual assessments (Tables 1 and 2 ) and TEWL measures were taken before and after 1 and 2 weeks of product use. Assessments were completed after a 30-min acclimation by evaluators who were blinded to product assignment. One evaluator per site conducted all visual and TEWL assessments. The evaluators were qualified health professionals experienced with visual grading. In order to promote consistency, they discussed process and areas of potential discrepancy prior to the start of the study. The same TEWL instrument and operator per site were used for all subjects. A sensory (comfort) assessment was obtained at study completion, including seven attributes using a 5-point scale rating: (1) overall size, (2) waist fit, (3) leg fit; and (4) overall comfort, (5) skin comfort in the waist, (6) leg, and (7) crotch areas. Subjects were asked to report any changes in health experienced during the course of the study. AEs were recorded and reported from the first until the last study assessment as received by study subjects during site visits and/or on phone calls, or captured on study questionnaires.
Two products were tested in this study. All subjects determined eligible were randomly assigned to a product following stratification based on the self-reported amount of daily incontinence (number of protective underwear typically used per day), the presence of diabetes, and waist measurement in order to control for factors having a major impact on skin health effects. A balance and assignment program within a web-based, validated, Electronic Records/Electronic Signature-compliant platform (21 CFR Part 11) was used. This was a single-blind study. The skin grader was blinded to the identity of the test materials, and randomization was generated and maintained by a statistician independent of the project.
Statistical analysis was conducted using the intent-to-treat (ITT) population. Data were summarized with descriptive statistics and analyses were conducted using generalized linear mixed models with the product as fixed effect, and subject as random effect. Baseline scores were used as a covariate. Study site, treatment week (visit number), and diabetic status were included in the model for overall analysis. Treatment week was included for the subgroup of diabetics and non-diabetics analysis. An empirical (sandwich) variance estimator was implemented along with a small sample bias correction (14) . Overall assessment of comfort was summarized by protective underwear group (i.e. frequency distributions) and compared via a Cochran-Mantel-Haenszel test. AE's were summarized by incidence, severity, causality, and recoverability. Approximately 120 subjects were to be randomized to complete at least 50 per group. This study sample size was based on previous adult incontinence studies (unpublished data), allowing detection of average erythema change from baseline difference of 0.2 between experimental and marketed product at 0.05 alpha level with 90% power. All analyses and graphs were completed using SAS â (Cary, NC, USA), Version 9.4.
Results
Disposition, demographics, and baseline characteristics One hundred and twenty-two subjects comprised the ITT population (Fig. 1) , with 98 (80%) at the Florida site and 24 (20%) at the Texas site. The demographic and baseline characteristics were similar across both products ( Table 3 ). The total number of products used, wear time, and weight of the used protective underwear were similar across both products (Table 4) .
Adverse events
Seven AEs were reported in seven subjects. None were serious, and no withdrawals occurred due to AEs. Five AEs were definitely not related to product per principal investigator (PI): sore throat, head congestion, gastric distress, abrasion on posterior left thigh, and tension headache. Two AEs were related to product: (1) subject had perineum erythema grade of 2.0 or 'moderate erythema' after 1 week (PI AE severity and relationship with treatment determination: 'mild, normal activities unaltered'; probably related to treatment); (2) subject had labia majora and perineum erythema grade 4.0 or 'moderate-to-severe erythema and/or edema' after 2 weeks (PI AE severity and relationship with treatment determination: 'mild, normal activities unaltered'; possibly related to treatment). Both subjects used the marketed reference product; both AEs were resolved at follow-up.
Skin erythema
The (arithmetic) mean erythema profile was low and stable across treatment weeks for both experimental and marketed reference products and scores were lower at Week 2 than baseline (Fig. 2) . Erythema average scores for all anatomical sites were less than 0.6 (0.5 = 'faint, barely perceptible'), with highest scores at baseline. The lowest mean scores were observed at buttocks and mons pubis anatomical sites and the highest scores were at labia majora, labia minora, and perineum. The subjects on the experimental product had a lower baseline mean erythema score than those on the marketed reference product in four of six grading sites (buttocks, inner thighs, labia majora, and labia minora). Baseline scores were used as a covariate in analyses. Erythema change from baseline is summarized in Fig. 3 . For both products, in general, overall changes were small; ranging from À0.15 to 0.02. Subgroup analyses were conducted by: treatment week, Fitzpatrick Skin type, number of protective underwear used per day, subject waist size, size of protective underwear used, study center, and the presence/absence of diabetes. Overall, there were only small differences observed across both products (ranging from À0.26 to 0.06), and the few statistically significant differences favored the experimental product. There were no statistically significant differences between the two products for presence/absence of diabetes (See Fig. 4 ).
Skin marking (red marking and pressure marking) Overall, there were no statistically significant differences in the experimental product compared to the marketed reference product for red or pressure marking change from baseline, and the only statistically significant differences in a subgroup analysis by treatment week favored the experimental product and were observed at Week 1 for the back waist (P = 0.019 and P = 0.083) for red and pressure marking, respectively.
Transepidermal water loss
Transepidermal water loss results were not normally distributed, and a non-parametric method was used to perform product comparisons. Overall, there were very small, statistically insignificant differences between the two products.
Daily diary and final comfort questionnaire
The estimated probability of body leakage (0.85 -experimental, 0.93 -marketed reference) and leakage onto clothes (0.00 -experimental, and 0.01-marketed reference) reported from the daily diary was not statistically different between the two products. Descriptive statistics from the comfort questionnaire completed at the end of study product use demonstrated the majority of subjects rated both products as 'just right' with respect to overall size (82% experimental, 64% marketed reference), fit around the leg (76% experimental, 82% marketed reference), and fit around the waist (86% experimental, 68% marketed reference). The majority of subjects also rated overall comfort of the product (86% experimental, 66% marketed reference), skin comfort in the leg area (76% experimental, 73% marketed reference), and skin comfort in crotch area (71% experimental, 66% marketed reference) similarly as 'comfortable' or 'very comfortable.' The only significant difference was found for skin comfort in waist area (89% experimental, 70% marketed reference, P = 0.01) in favor of the experimental product. Fig. 2 . Mean erythema profile across the study. The majority of grading sites (4 of 6) for those subjects using the experimental product had a lower mean erythema score at baseline compared to the marketed reference product.
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Skin health effects and comfort
Discussion
It is important to confirm effects of product use on skin health for products intended for prolonged skin contact. A separate paper describes the detailed overall skin compatibility evaluation and testing program for the new incontinence product line up (3). This study evaluated skin health effects and comfort during typical conditions of use in current incontinent Fig. 3 . Change from baseline erythema visual skin grading at Week 2 for all grading sites *P = 0.050. Fig. 4 . Overall change from baseline erythema visual skin grading across all grading sites for the subgroup of diabetics and non-diabetics displayed with 95% CI. Mean differences to the left of the no-effect line indicate less erythema with the experimental product compared to the marketed reference product. There were no statistically significant differences between the two products.
protective underwear users over a 14-day time period. The study population included a majority (72%) of postmenopausal women and a subpopulation of diabetics to gain additional learning for known incontinence risk factors with increased potential for skin health issues. The study was sized to distinguish statistical differences in erythema between the experimental and marketed product. A clinically meaningful erythema difference is a change of 0.5 on the visual scoring scale. Overall, there were negligible (average scores across all anatomical sites were less than 0.6) erythema changes demonstrated across products. Higher mean erythema scores were observed with both products at labia majora, labia minora, and perineum, which is consistent with those reported for menstrual pads (10) , and appear to be more related to areas of pressure points due to contact with the product which may be influenced by product fit and individual activity. We collected information related to product comfort and fit as discussed below; however, did not collect information on daily activity in this study. In addition, the control (inner thigh) average values were either higher than or comparable to average test site scores across all anatomical sites, indicating erythema changes were not due to differences in product. Results for erythema within a subgroup of diabetics (n = 9 experimental, n = 13 marketed reference product) did not demonstrate statistical difference between products. The subgroup was small, and results were variable. Therefore, results for the diabetic subgroup should be verified in an appropriate sized study to draw firm conclusions.
Exploratory outcomes
Skin marking is cosmetic and transient in nature and correlates with product fit. Changes from baseline between products demonstrated improvement from baseline and no statistical differences between products for skin marking. One explanation for the improvement in skin marking may be due to appropriate sizing of the protective underwear assignment by waist measurement within the study vs. possible underestimation of true body measurements and therefore tighter fit of 'usual product' baseline protective underwear. In-use sensory assessments demonstrated overall good fit and skin comfort for both products with no statistical differences between the products.
Transepidermal water loss (12) is a reliable and valid measure in children and adults. Low TEWL rates correlate with intact skin barrier function and high TEWL rates are indicative of increased water loss and poor barrier function (15) (16) (17) (18) . The overall TEWL profile was similar between products, with no statistically significant differences found between the two products. Median values were comparable between products, higher than reported in the literature for healthy continent women (19, 20) , and consistent with TEWL results reported in a small study of incontinent adults (21) . Median TEWL values for the control site (inner thigh) were comparable between products and higher than values obtained for buttocks, providing evidence of negligible overall product-related erythema in the buttock area. Labia majora had highest values, which is consistent with literature and indicates more compromised skin at pressure point areas vs. product related. Limitations of TEWL measure in this population include potential confounding factors inherent in this testing, such as: measuring a semioccluded anatomical site due to an overall obese population with excessive skin folds (skin-to-skin contact), hydrated tissue due to sweat glands, urine leaks inherent for incontinent population, and measurement proximity to the vaginal opening. Results were skewed, with some high values (11 of 810, 1% of assessments) out of expected VapoMeter measurement range (greater than 200 g/m 2 per hour), occurring at labia majora for some subjects assigned a large or extra-large product. There was no correlation with prevalence of diabetes, or erythema scoring, nor any AE reported for these high values, and all TEWL values for ITT population were included in the study analyses.
Conclusion
This study confirmed, in a real-use context during 14-days of continued use, the skin health effects of experimental protective underwear as compared to a currently marketed reference product in a population with known incontinence comorbidity and increased potential for skin health issues (majority postmenopausal, majority obese, 18% Type II diabetics). There were few statistical differences or trends in statistical significance between the experimental and currently marketed reference product across all assessments. Subjective reporting of in-use sensory assessments (skin comfort and product fit) supports these results. Both products were well-tolerated by the subjects with no product-related AEs associated with the experimental product.
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